Main Menu

Professor Christopher Nutting

Group Leader

The alt text
Professor Christopher Nutting works as a Consultant Clinical Oncologist at The Royal Marsden. He was instrumental in the testing and implementation on IMRT in the UK and its adoption as a new standard of care Worldwide. ORCID 0000-0003-4754-9183


Professor Christopher Martin Nutting qualified from Portsmouth Grammar School in 1986 and from University College and Middlesex Hospital School of Medicine (University of London) in 1992.

He was awarded 1st Class BSc Honours (Medicine and Cell Pathology, University of London) in 1989 and MB BS (University of London) 1992. He became a Member of the Royal College of Physicians (UK) 1995 and Fellow of the Royal College of Radiologists (UK) in 1998. In 1999 he was awarded Certification of European Society of Medical Oncology. Following a period of study at Imperial College Business School he was awarded the Advanced Certificate in Health Care Management (University of London) in 2000. Between 1998 and 2001 he studied for a Medical Doctorate (MD Res) at The Institute of Cancer Research, University of London, which he was awarded in 2001. He was awarded PhD from City University in 2012.

He was appointed Consultant Clinical Oncologist at The Royal Marsden Hospital and Honorary Senior Lecturer in Clinical Oncology at The Institute of Cancer Research in 2001. He was Clinical Director of the Head and Neck Unit at The Royal Marsden Hospital in 2002-2020. In 2003-2006 he was the National Clinical Lead in Head and Neck Cancer for the Department of Health (UK) and the Cancer Services Collaborative. He joined the National Cancer Research Institute Committee (NCRI) Head and Neck Cancer Clinical Studies Group (CSG) in 2003 and was Chairman of the CSG in 2006-2012. During his 6-year period as Chair, the CSG became the highest performing rare cancer with an increase in national clinical trial recruitment to record levels. He was National Clinical Oncology advisor to the Data for Head and Neck Oncology (DAHNO) project 2005-2010.

In 2007-2010 he was President of the British Oncological Association. In 2009 he was appointed Co-Chair of The Clinical and Translational Radiotherapy and Radiobiology Working Group of the NCRI.

He is currently President of the Royal Society of Medicine Oncology Section.

Since 2019 he had been Chair of the NCRI UK Proton Beam Therapy Research Group in the UK responsible for research in the NHS’s £250M Proton Beam facilities.

He remains Clinical Director at The Royal Marsden Hospital responsible for the new diagnostic and treatment centre in Cavendish Square.

Professor Christopher Nutting is Principal Investigator for a number of research trials including the Cancer Research UK sponsored PARSPORT, COSTAR, ARTDECO and DARS Trials. He is joint holder of CRUK program grant “Physical and biological optimisation of radiotherapy in head and neck cancer”. He is principle or co-investigator on an additional 15 trials in head and neck cancer sponsored by The Royal Marsden Hospital or by the pharmaceutical industry. He is Principal and/or Co-investigator of research grants for advancement of radiotherapy and chemotherapy research from Cancer Research UK, HTA, and the pharmaceutical industry. As a regular contributor to International medical publications and meetings, he has published over 300 articles in his areas of expertise. He has received National and International Awards and Professorships for his advances in research into head and neck cancer radiotherapy. In 2018 he was elected Fellow of the Academy of Medical Sciences, one of the youngest doctors to be awarded this accolade.